Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series

被引：15

作者：

Chiari, Rita ^{[1
]}

Buttitta, Fiamma ^{[2
]}

Iacono, Daniela ^{[1
]}

Bennati, Chiara ^{[1
]}

Metro, Giulio ^{[1
]}

Di Lorito, Alessia ^{[2
]}

Iezzi, Manuela ^{[2
]}

Tiseo, Marcello ^{[3
]}

Mazzoni, Francesca ^{[4
]}

Cappuzzo, Federico ^{[5
]}

Marchetti, Antonio ^{[2
]}

Crino, Lucio ^{[1
]}

机构：

[1] Osped Santa Maria Misericordia, Dept Med Oncol, I-06132 Perugia, Italy

[2] Univ Fdn, CeSI, Ctr Predict Mol Med, Chieti, Italy

[3] Univ Hosp, Dept Med Oncol, Parma, Italy

[4] Careggi Hosp Firenze, Dept Med Oncol, Florence, Italy

[5] Ist Toscano Tumori Livorno, Dept Med Oncol, Livorno, Italy

来源：

CLINICAL LUNG CANCER | 2014年 / 15卷 / 06期

关键词：

Crizotinib; FISH; IHC; NSCLC; ROS1; CANCER;

D O I：

10.1016/j.cllc.2014.06.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung adenocarcinoma harboring the c-ros oncogene 1 (ROS1) translocations represents a newly discovered molecular subset of non small cell lung cancer (NSCLC. Just as with anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials have shown a high response rate to crizotinib in these patients. Fluorescent in situ hybridization (FISH) is considered the reference standard for detecting ROS1 translocations and ALK rearrangements. Several anti-ROS1 antibodies are in Use, and the first results have suggested that immunohistochemistry (IHC) Mild, be a suitable tool for identifying ROS1 rearrangement. The results from this small series suggest that IHC is a valuable tool, for identifying ROS1 rearrangement and have confirmed that this Subset of patients can benefit from crizotinib-based treatment.

引用

页码：470 / 474

页数：5

共 6 条

[1] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[2]

Ou SHI, 2013, J THORAC ONCOL, V8, pS295

[3] Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer [J].

Rikova, Klarisa ;

Guo, Ailan ;

Zeng, Qingfu ;

Possemato, Anthony ;

Yu, Jian ;

Haack, Herbert ;

Nardone, Julie ;

Lee, Kimberly ;

Reeves, Cynthia ;

Li, Yu ;

Hu, Yerong ;

Tan, Zhiping ;

Stokes, Matthew ;

Sullivan, Laura ;

Mitchell, Jeffrey ;

Wetzel, Randy ;

MacNeill, Joan ;

Ren, Jian Min ;

Yuan, Jin ;

Bakalarski, Corey E. ;

Villen, Judit ;

Kornhauser, Jon M. ;

Smith, Bradley ;

Li, Daiqiang ;

Zhou, Xinmin ;

Gygi, Steven P. ;

Gu, Ting-Lei ;

Polakiewicz, Roberto D. ;

Rush, John ;

Comb, Michael J. .

CELL, 2007, 131 (06) :1190-1203

[4] Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion [J].

Rimkunas, Victoria M. ;

Crosby, Katherine E. ;

Li, Daiqiang ;

Hu, Yerong ;

Kelly, Meghan E. ;

Gu, Ting-Lei ;

Mack, Jennifer S. ;

Silver, Matthew R. ;

Zhou, Xinmin ;

Haack, Herbert .

CLINICAL CANCER RESEARCH, 2012, 18 (16) :4449-4457

[5] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Kim, Dong-Wan ;

Nakagawa, Kazuhiko ;

Seto, Takashi ;

Crino, Lucio ;

Ahn, Myung-Ju ;

De Pas, Tommaso ;

Besse, Benjamin ;

Solomon, Benjamin J. ;

Blackhall, Fiona ;

Wu, Yi-Long ;

Thomas, Michael ;

O'Byrne, Kenneth J. ;

Moro-Sibilot, Denis ;

Camidge, D. Ross ;

Mok, Tony ;

Hirsh, Vera ;

Riely, Gregory J. ;

Iyer, Shrividya ;

Tassell, Vanessa ;

Polli, Anna ;

Wilner, Keith D. ;

Jaenne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394

[6] MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations [J].

Tanizaki, Junko ;

Okamoto, Isamu ;

Okamoto, Kunio ;

Takezawa, Ken ;

Kuwata, Kiyoko ;

Yamaguchi, Haruka ;

Nakagawa, Kazuhiko .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (10) :1624-1631

← 1 →